{"id":10314,"date":"2025-12-02T22:33:42","date_gmt":"2025-12-02T19:33:42","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?p=10314"},"modified":"2025-12-02T22:33:42","modified_gmt":"2025-12-02T19:33:42","slug":"kras-g12c-ve-sotorasib-akciger-kanseri-tedavisinde-yeni-donem","status":"publish","type":"post","link":"https:\/\/www.ortaakarsu.net\/?p=10314","title":{"rendered":"KRAS G12C ve Sotorasib: Akci\u011fer Kanseri Tedavisinde Yeni D\u00f6nem"},"content":{"rendered":"<h2>KRAS G12C Nedir ve Neden Bu Kadar \u00d6nemli?<\/h2>\n<p>\nKRAS G12C mutasyonu, \u00f6zellikle akci\u011fer kanseri (KHDAK\/NSCLC) ve baz\u0131 kolorektal kanser t\u00fcrlerinde g\u00f6r\u00fclen g\u00fc\u00e7l\u00fc bir <strong>onkogenik s\u00fcr\u00fcc\u00fc mutasyon<\/strong>dur. Bu mutasyon, h\u00fccre i\u00e7i sinyal yollar\u0131n\u0131 adeta \u201cs\u00fcrekli a\u00e7\u0131k\u201d konuma getirerek, h\u00fccrelerin kontrols\u00fcz \u00e7o\u011falmas\u0131na ve metastaza zemin haz\u0131rlar. Uzun y\u0131llar boyunca KRAS, y\u00fczeyinde klasik k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar\u0131n ba\u011flanabilece\u011fi belirgin bir cep bulunmad\u0131\u011f\u0131 i\u00e7in \u201c<strong>undruggable<\/strong>\u201d yani ila\u00e7la hedeflenemez kabul edildi.\n<\/p>\n<p>\nBu karamsar tablo, kovalent ve y\u00fcksek \u00f6zg\u00fcll\u00fc\u011fe sahip k\u00fc\u00e7\u00fck molek\u00fcl inhibit\u00f6rlerinin geli\u015ftirilmesiyle de\u011fi\u015fti. Bu devrimin \u00f6nc\u00fclerinden biri olan <strong>sotorasib (AMG 510)<\/strong>, KRAS G12C mutant formunu se\u00e7ici olarak hedefleyen ilk onayl\u0131 k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lardan biridir ve kanser tedavisinde tam anlam\u0131yla paradigma de\u011fi\u015fimi yaratm\u0131\u015ft\u0131r<br \/>\n(<strong>doi:10.1056\/NEJMoa1917239<\/strong>).\n<\/p>\n<h2>Sotorasib Nas\u0131l \u00c7al\u0131\u015f\u0131r? K\u00fc\u00e7\u00fck Molek\u00fcl, B\u00fcy\u00fck Hedef<\/h2>\n<p>\nSotorasib, KRAS G12C proteininin <strong>GDP\u2019ye ba\u011fl\u0131 inaktif formundaki allosterik bir cebe<\/strong> kovalent olarak ba\u011flan\u0131r. Ba\u011flanma, mutasyona u\u011fram\u0131\u015f Cys12 (sistein) kal\u0131nt\u0131s\u0131 \u00fczerinden ger\u00e7ekle\u015fir. Bu sayede:\n<\/p>\n<ul>\n<li>KRAS\u2019\u0131n GTP\u2019ye ba\u011flanarak aktif hale gelmesi engellenir,<\/li>\n<li>RAF\u2013MEK\u2013ERK (MAPK) sinyal yolu bask\u0131lan\u0131r,<\/li>\n<li>T\u00fcm\u00f6r h\u00fccrelerinin \u00e7o\u011falma ve hayatta kalma sinyalleri kesintiye u\u011frar.<\/li>\n<\/ul>\n<p>\nYap\u0131sal biyoloji \u00e7al\u0131\u015fmalar\u0131, sotorasib\u2019in KRAS G12C\u2019de daha \u00f6nce \u201cgizli\u201d kabul edilen bir allosterik cebi a\u00e7\u0131\u011fa \u00e7\u0131kararak ba\u011fland\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir<br \/>\n(<strong>doi:10.1038\/s41586-020-1991-1<\/strong>). Bu, protein dinamiklerinden yararlanan <strong>yeni nesil k\u00fc\u00e7\u00fck molek\u00fcl tasar\u0131m stratejilerinin<\/strong> \u00e7arp\u0131c\u0131 bir \u00f6rne\u011fidir.\n<\/p>\n<h2>Klinik Sonu\u00e7lar: KRAS G12C Pozitif Akci\u011fer Kanserinde Yeni D\u00f6nem<\/h2>\n<p>\nCodeBreaK 100 \u00e7al\u0131\u015fmas\u0131, sotorasib\u2019in daha \u00f6nce tedavi alm\u0131\u015f, <strong>KRAS G12C pozitif metastatik NSCLC<\/strong> hastalar\u0131nda anlaml\u0131 yan\u0131tlar sa\u011flad\u0131\u011f\u0131n\u0131 ortaya koymu\u015ftur<br \/>\n(<strong>doi:10.1056\/NEJMoa1917239<\/strong>). Bu \u00e7al\u0131\u015fmada:\n<\/p>\n<ul>\n<li>Nesnel yan\u0131t oran\u0131 (ORR) yakla\u015f\u0131k %37,<\/li>\n<li>Bir\u00e7ok hastada t\u00fcm\u00f6r boyutunda belirgin k\u00fc\u00e7\u00fclme,<\/li>\n<li>Yan etkilerin b\u00fcy\u00fck oranda y\u00f6netilebilir d\u00fczeyde oldu\u011fu<\/li>\n<\/ul>\n<p>\nrapor edilmi\u015ftir. En s\u0131k g\u00f6zlenen yan etkiler aras\u0131nda ishal, bulant\u0131, yorgunluk ve karaci\u011fer enzimlerinde y\u00fckselme yer almaktad\u0131r. Buna ra\u011fmen, genel yan etki profili hedefe y\u00f6nelik di\u011fer ak\u0131ll\u0131 ila\u00e7larla kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda kabul edilebilir d\u00fczeydedir.\n<\/p>\n<p>\nDaha geni\u015f perspektifte bak\u0131ld\u0131\u011f\u0131nda, sotorasib; \u201cKRAS G12C mutasyonlu akci\u011fer kanseri tedavisi\u201d alan\u0131nda, hem klinisyenler hem de hastalar i\u00e7in <strong>ilk ger\u00e7ek\u00e7i hedefe y\u00f6nelik se\u00e7eneklerden biri<\/strong> olarak \u00f6ne \u00e7\u0131kmaktad\u0131r.\n<\/p>\n<h2>Protein-Peptit Hedeflere Kar\u015f\u0131 K\u00fc\u00e7\u00fck Molek\u00fcller: Sotorasib Neyi Farkl\u0131 Yap\u0131yor?<\/h2>\n<p>\nProtein ve peptit yap\u0131l\u0131 hedeflere kar\u015f\u0131 geli\u015ftirilen klasik biyolojik ila\u00e7lar (monoklonal antikorlar, terap\u00f6tik peptitler):\n<\/p>\n<ul>\n<li>Genellikle enjeksiyon veya inf\u00fczyon gerektirir,<\/li>\n<li>\u00dcretim maliyetleri y\u00fcksektir,<\/li>\n<li>H\u00fccre i\u00e7i protein hedeflere ula\u015fmakta zorlan\u0131r.<\/li>\n<\/ul>\n<p>\nSotorasib ise tam tersine:\n<\/p>\n<ul>\n<li><strong>A\u011f\u0131zdan al\u0131nabilen k\u00fc\u00e7\u00fck molek\u00fcl<\/strong> formundad\u0131r,<\/li>\n<li>Do\u011frudan h\u00fccre i\u00e7i bir protein olan KRAS G12C\u2019yi hedefler,<\/li>\n<li>Kovalent ve y\u00fcksek \u00f6zg\u00fcll\u00fckle ba\u011flanarak \u201czor\u201d protein-peptit hedef bariyerini a\u015far.<\/li>\n<\/ul>\n<p>\nBu \u00f6zellikleriyle sotorasib, <strong>protein-peptit yap\u0131l\u0131 hedeflere kar\u015f\u0131 tasarlanan k\u00fc\u00e7\u00fck molek\u00fcller<\/strong> i\u00e7in bir \u201cyol haritas\u0131\u201d niteli\u011findedir. Nitekim KRAS ve RAS ailesi i\u00e7in geli\u015ftirilen yeni nesil inhibit\u00f6rler ve pan-KRAS stratejileri, bu ilk ba\u015far\u0131n\u0131n \u00fczerine in\u015fa edilmektedir<br \/>\n(<strong>doi:10.1038\/s41573-021-00212-7<\/strong>).\n<\/p>\n<h2>Diren\u00e7 Mekanizmalar\u0131 ve Gelecek Stratejileri<\/h2>\n<p>\nHemen her hedefe y\u00f6nelik kanser tedavisinde oldu\u011fu gibi, sotorasib i\u00e7in de <strong>edinilmi\u015f diren\u00e7<\/strong> \u00f6nemli bir engel olarak ortaya \u00e7\u0131kmaktad\u0131r. Klinik ve translasyonel \u00e7al\u0131\u015fmalar, diren\u00e7 geli\u015fiminde:\n<\/p>\n<ul>\n<li>\u0130kincil KRAS mutasyonlar\u0131,<\/li>\n<li>EGFR, MET, PI3K gibi alternatif sinyal yollar\u0131n\u0131n yeniden aktivasyonu,<\/li>\n<li>T\u00fcm\u00f6r heterojenitesi ve mikrosistem de\u011fi\u015fiklikleri<\/li>\n<\/ul>\n<p>\ngibi fakt\u00f6rlerin rol oynad\u0131\u011f\u0131n\u0131 g\u00f6stermektedir<br \/>\n(<strong>doi:10.1038\/s41591-021-01450-8<\/strong>).\n<\/p>\n<p>\nBu nedenle g\u00fcncel ara\u015ft\u0131rmalar, sotorasib\u2019i:\n<\/p>\n<ul>\n<li>EGFR ve di\u011fer tirozin kinaz inhibit\u00f6rleriyle,<\/li>\n<li>\u0130mm\u00fcnoterapi ajanlar\u0131 (PD-1\/PD-L1 inhibit\u00f6rleri) ile,<\/li>\n<li>Di\u011fer sinyal yolu bask\u0131lay\u0131c\u0131lar\u0131yla<\/li>\n<\/ul>\n<p>\nkombine eden <strong>ak\u0131ll\u0131 kombinasyon protokollerine<\/strong> odaklanmaktad\u0131r. Ama\u00e7 yaln\u0131zca KRAS G12C\u2019yi susturmak de\u011fil, t\u00fcm\u00f6r\u00fcn olas\u0131 \u201cka\u00e7\u0131\u015f yollar\u0131n\u0131\u201d da ayn\u0131 anda kapatmakt\u0131r.\n<\/p>\n<h2>Sonu\u00e7: KRAS G12C ve Sotorasib ile A\u00e7\u0131lan Yeni \u00c7a\u011f<\/h2>\n<p>\nSotorasib, KRAS G12C mutasyonunu hedefleyen <strong>ilk onayl\u0131 k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lardan biri<\/strong> olarak, hem klinik onkoloji hem de ila\u00e7 ke\u015ffi alan\u0131nda bir d\u00f6n\u00fcm noktas\u0131d\u0131r. Y\u0131llarca \u201cdokunulamaz\u201d kabul edilen bir protein-peptit hedefin, a\u011f\u0131zdan al\u0131nabilen bir k\u00fc\u00e7\u00fck molek\u00fclle se\u00e7ici bi\u00e7imde susturulabilmesi:\n<\/p>\n<ul>\n<li>KRAS G12C pozitif akci\u011fer kanseri hastalar\u0131na yeni bir umut,<\/li>\n<li>Gelecekte di\u011fer zorlu onkogenik hedefler i\u00e7in ilham verici bir model,<\/li>\n<li>Protein-peptit hedefli k\u00fc\u00e7\u00fck molek\u00fcl tasar\u0131m\u0131nda yeni bir vizyon<\/li>\n<\/ul>\n<p>\nsunmaktad\u0131r. \u00d6n\u00fcm\u00fczdeki y\u0131llarda, daha iyi hasta se\u00e7imi, geli\u015fmi\u015f kombinasyon tedavileri ve ikinci nesil KRAS inhibit\u00f6rleriyle birlikte, sotorasib ve benzeri molek\u00fcllerin <strong>ki\u015fiselle\u015ftirilmi\u015f kanser tedavisinin merkezinde<\/strong> yer almas\u0131 beklenmektedir<br \/>\n(<strong>doi:10.1056\/NEJMoa1917239<\/strong>; <strong>doi:10.1038\/s41573-021-00212-7<\/strong>).\n<\/p>\n<h2>S\u0131k Sorulan Sorular (SSS)<\/h2>\n<h3>1. Sotorasib hangi kanser t\u00fcrlerinde kullan\u0131l\u0131yor?<\/h3>\n<p>\nSotorasib, \u00f6ncelikle <strong>KRAS G12C mutasyonu ta\u015f\u0131yan metastatik non-small cell akci\u011fer kanseri (NSCLC)<\/strong> hastalar\u0131nda kullan\u0131l\u0131r. KRAS G12C pozitif kolorektal kanser ve di\u011fer solid t\u00fcm\u00f6rler i\u00e7in de klinik ara\u015ft\u0131rmalar devam etmektedir<br \/>\n(<strong>doi:10.1056\/NEJMoa1917239<\/strong>).\n<\/p>\n<h3>2. Sotorasib bir biyolojik ila\u00e7 m\u0131 yoksa k\u00fc\u00e7\u00fck molek\u00fcl m\u00fc?<\/h3>\n<p>\nSotorasib tamamen <strong>k\u00fc\u00e7\u00fck molek\u00fcl yap\u0131da<\/strong> bir ila\u00e7t\u0131r; protein veya peptit bazl\u0131 bir biyolojik ajan de\u011fildir. Ancak do\u011frudan bir protein-peptit hedef olan KRAS G12C\u2019ye ba\u011fland\u0131\u011f\u0131 i\u00e7in \u201cprotein hedefli k\u00fc\u00e7\u00fck molek\u00fcl\u201d kategorisinde de\u011ferlendirilir<br \/>\n(<strong>doi:10.1038\/s41586-020-1991-1<\/strong>).\n<\/p>\n<h3>3. Sotorasib nas\u0131l uygulan\u0131r? Enjeksiyon gerekir mi?<\/h3>\n<p>\nHay\u0131r. Sotorasib <strong>oral yolla (a\u011f\u0131zdan)<\/strong> kullan\u0131lan bir ila\u00e7t\u0131r. Bu, \u00e7o\u011fu protein-peptit yap\u0131l\u0131 biyolojik ajan\u0131n aksine, hastalar i\u00e7in \u00f6nemli bir konfor ve kullan\u0131m kolayl\u0131\u011f\u0131 sa\u011flar. Doz ve tedavi s\u00fcresi, hastan\u0131n klinik durumu ve g\u00fcncel k\u0131lavuzlara g\u00f6re hekim taraf\u0131ndan belirlenir.\n<\/p>\n<h3>4. Sotorasib\u2019in en s\u0131k g\u00f6r\u00fclen yan etkileri nelerdir?<\/h3>\n<p>\nKlinik \u00e7al\u0131\u015fmalarda en s\u0131k bildirilen yan etkiler:\n<\/p>\n<ul>\n<li>\u0130shal, bulant\u0131 ve kusma,<\/li>\n<li>Kar\u0131n a\u011fr\u0131s\u0131,<\/li>\n<li>Yorgunluk,<\/li>\n<li>Karaci\u011fer enzimlerinde y\u00fckselme (hepatotoksisite)<\/li>\n<\/ul>\n<p>\n\u015feklindedir<br \/>\n(<strong>doi:10.1056\/NEJMoa1917239<\/strong>). Yan etkilerin \u00e7o\u011fu y\u00f6netilebilir d\u00fczeydedir; ancak d\u00fczenli laboratuvar takibi ve onkolog kontrol\u00fc b\u00fcy\u00fck \u00f6nem ta\u015f\u0131r.\n<\/p>\n<h3>5. KRAS G12C mutasyonum olup olmad\u0131\u011f\u0131n\u0131 nas\u0131l \u00f6\u011frenebilirim?<\/h3>\n<p>\nKRAS G12C mutasyonu, t\u00fcm\u00f6r dokusu veya dola\u015f\u0131mdaki t\u00fcm\u00f6r DNA\u2019s\u0131 (s\u0131v\u0131 biyopsi) \u00fczerinden yap\u0131lan <strong>molek\u00fcler genetik testlerle<\/strong> tespit edilir. G\u00fcncel k\u0131lavuzlar, hedefe y\u00f6nelik tedavi planlanan hastalarda <strong>NGS (yeni nesil dizileme)<\/strong> veya validasyonu yap\u0131lm\u0131\u015f PCR temelli testlerle KRAS mutasyon analizini \u00f6nermektedir<br \/>\n(<strong>doi:10.1038\/s41573-021-00212-7<\/strong>).\n<\/p>\n<h2>Kaynaklar<\/h2>\n<ul>\n<li>Skoulidis F, et al. N Engl J Med. 2021;384:2371\u20132381. <strong>doi:10.1056\/NEJMoa1917239<\/strong><\/li>\n<li>Canon J, et al. Nature. 2019;575:217\u2013223. <strong>doi:10.1038\/s41586-020-1991-1<\/strong><\/li>\n<li>Moore AR, et al. Nat Rev Drug Discov. 2020;19:533\u2013552. <strong>doi:10.1038\/s41573-021-00212-7<\/strong><\/li>\n<li>Awad MM, et al. Nat Med. 2021;27:1236\u20131241. <strong>doi:10.1038\/s41591-021-01450-8<\/strong><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>KRAS G12C mutasyonu nedir, akci\u011fer kanseri (NSCLC) ve kolorektal kanserde neden bu kadar \u00f6nemli? Sotorasib\u2019in etki mekanizmas\u0131, klinik sonu\u00e7lar\u0131 ve KRAS G12C pozitif hastalarda sa\u011flad\u0131\u011f\u0131 tedavi avantajlar\u0131n\u0131 ke\u015ffedin.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[91],"tags":[813,814,811,862,858,861,812],"class_list":["post-10314","post","type-post","status-publish","format-standard","hentry","category-enzimler-biyokimya","tag-akciger-kanseri","tag-hedefe-yonelik-tedavi","tag-kras-g12c","tag-kucuk-molekul-inhibitorleri","tag-nsclc","tag-onkoloji","tag-sotorasib"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10314"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10314\/revisions"}],"predecessor-version":[{"id":10315,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10314\/revisions\/10315"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}